A Phase I clinical trial investigating CD19-CAR-T cells for relapsed/refractory CD19+ leukemia revealed that an elevated frequency of LAG-3+/TNF-αlowCD8+ T cells in peripheral blood prior to the cell infusion, along with the expression of exhaustion markers, was correlated with ultimate treatment failure [49,50]. Here, CD19 is linked to leukemia.